Hidetaka Nomura1, Masayuki Sekine2, Shiro Yokoyama3, Masami Arai4, Takayuki Enomoto2, Nobuhiro Takeshima5, Seigo Nakamura3. 1. The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-ku, Tokyo, 135-8550, Japan. hidetaka.nomura@jfcr.or.jp. 2. Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan. 3. Breast Center, Showa University, Tokyo, Japan. 4. Diagnostics and Therapeutics of Intractable Diseases, Juntendo University, Graduate School of Medicine, Tokyo, Japan. 5. The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-ku, Tokyo, 135-8550, Japan.
Abstract
BACKGROUND: This study aimed to identify the clinical background and treatment outcomes of risk-reducing salpingo-oophorectomy (RRSO) in Japan for women with hereditary breast and ovarian cancer (HBOC). METHODS: In the present retrospective observational study, we examined the Japanese HBOC Consortium's (JHC) database. This database contains 11,711 probands who received BRCA genetic testing, or their relatives, with any cancer in 2433 pedigrees. This study was supported by the registration committee of the JHC. RESULTS: We analyzed 488 individuals diagnosed with HBOC, of which 153 (31.4%) underwent RRSO. Of the latter patients, 88 carried BRCA1 mutation (B1); 62 carried BRCA2 mutation (B2); and 3 carried both mutations. During a mean follow-up period of 2.6 years (range 0-12.6), one patient developed a primary peritoneal cancer (PPC). Clinical background comparison for individuals who underwent RRSO vs. those > 45 years of age who did not undergo RRSO revealed that significant factors were represented by B1 (p < 0.0001); child bearing (p < 0.00001); and breast cancer history (p < 0.01). However, family history of ovarian cancer and menopause status were not significantly different. CONCLUSION: Over 30% HBOC's in Japan underwent RRSO. In Japan, individuals with breast cancer history and B1 generally underwent RRSO, whereas those who did not bear a child mostly avoided RRSO.
BACKGROUND: This study aimed to identify the clinical background and treatment outcomes of risk-reducing salpingo-oophorectomy (RRSO) in Japan for women with hereditary breast and ovarian cancer (HBOC). METHODS: In the present retrospective observational study, we examined the Japanese HBOC Consortium's (JHC) database. This database contains 11,711 probands who received BRCA genetic testing, or their relatives, with any cancer in 2433 pedigrees. This study was supported by the registration committee of the JHC. RESULTS: We analyzed 488 individuals diagnosed with HBOC, of which 153 (31.4%) underwent RRSO. Of the latter patients, 88 carried BRCA1 mutation (B1); 62 carried BRCA2 mutation (B2); and 3 carried both mutations. During a mean follow-up period of 2.6 years (range 0-12.6), one patient developed a primary peritoneal cancer (PPC). Clinical background comparison for individuals who underwent RRSO vs. those > 45 years of age who did not undergo RRSO revealed that significant factors were represented by B1 (p < 0.0001); child bearing (p < 0.00001); and breast cancer history (p < 0.01). However, family history of ovarian cancer and menopause status were not significantly different. CONCLUSION: Over 30% HBOC's in Japan underwent RRSO. In Japan, individuals with breast cancer history and B1 generally underwent RRSO, whereas those who did not bear a child mostly avoided RRSO.
Entities:
Keywords:
BRCA; Hereditary breast and ovarian cancers; Risk-reducing salpingo-oophorectomy
Authors: Diane Stirling; D Gareth R Evans; Gabriella Pichert; Andrew Shenton; Elaine N Kirk; Sylvia Rimmer; C Michael Steel; Sheila Lawson; R M Camille Busby-Earle; Jane Walker; Fiona I Lalloo; Diana M Eccles; Anneke M Lucassen; Mary E Porteous Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Walter A Rocca; Brandon R Grossardt; Mariza de Andrade; George D Malkasian; L Joseph Melton Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: M J A Kenkhuis; G H de Bock; P Oude Elferink; H J G Arts; J C Oosterwijk; L Jansen; M J E Mourits Journal: Maturitas Date: 2010-04-21 Impact factor: 4.342
Authors: Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Joanna B Madalinska; Marc van Beurden; Eveline M A Bleiker; Heiddis B Valdimarsdottir; Lottie Lubsen-Brandsma; Leon F Massuger; Marian J E Mourits; Katja N Gaarenstroom; Eleonora B L van Dorst; Hans van der Putten; Henk Boonstra; Neil K Aaronson Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: Angela R Bradbury; Comfort N Ibe; James J Dignam; Shelly A Cummings; Marion Verp; Melody A White; Grazia Artioli; Laura Dudlicek; Olufunmilayo I Olopade Journal: Genet Med Date: 2008-03 Impact factor: 8.822